http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CO-6220963-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_938a6d7a15cbc93a74abe1953eb25d47 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0812 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-07 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-07 |
| filingDate | 2009-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28e93c2db7149df37cde2eae52915560 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9afe97eb7195d9eed4ba89cf0bdeaa1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e243994010c6fa4a8e581c2a16cf19af http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ba272bbea02936d834ad5b57fd858c4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0240ea5b2448f5944fad1bbd7321da42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_787559d8f26321f669566dddb26ad3a3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ff086307135be23fa42bb1ffd3cebc0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2bcda484c92fa0d95ae8ffccaca12681 |
| publicationDate | 2010-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CO-6220963-A2 |
| titleOfInvention | COCRISTALS AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM |
| abstract | 1. A co-crystal comprising VX-950 and 4-hydroxybenzoic acid. 2. The co-crystal according to claim 1, wherein the molar ratio of VX-950 and 4-hydroxybenzoic acid is in the range of 5: 1 to 1: 5. 3. The co-crystal according to claim 2, wherein the molar ratio of VX-950 and 4-hydroxybenzoic acid is 1: 1. 4. The co-crystal according to claim 3, which has at least two of the four powder x-ray diffraction peaks at 17.61, 18.07, 18.87, 19.68, and 20.75 ° 2-Theta, each with a standard deviation of +/- 0.3 ° 2-Theta. 5. The co-crystal according to claim 3, which has a peak in its DSC thermogram at 191.19 ° C with a standard deviation of +/- 5 ° C. 6.- A co-crystal comprising VX-950; a co-crystal former selected from the group consisting of 4-aminosalicylic acid and 4-hydroxybenzoic acid; and a solvent selected from the group consisting of acetonitrile, ethyl acetate, ethanol, and acetone. 7. The co-crystal according to claim 6, wherein the solvent is acetonitrile. 8. The co-crystal according to claim 7, wherein the co-crystal former is 4- aminosalicylic acid. 9. The co-crystal according to claim 8, wherein the molar ratio of VX-950 and 4- aminosalicylic acid is in the range of 5: 1 to 1: 5. 10. The co-crystal according to claim 9, wherein the molar ratio of VX-950 and 4- aminosalicylic acid is 1: 1. 11. The co-crystal according to claim 10, wherein the molar ratio of VX-950 and acetonitrile is in the range of 1: 0.05 to 1: 1. 12. The co-crystal according to claim 11, wherein the molar ratio of VX-950 and acetonitrile is 1: 0.34. 13. The co-crystal according to claim 12, which has at least two of the four powder X-ray diffraction peaks at 7,711, 8,631, 9,723, and 9,959 ° 2-Theta, each with a standard deviation of + / - 0.3 ° 2-Theta. 14. The co-crystal according to claim 12, which has a DSC peak in its DSC thermogram at 184.71 ° C with a standard deviation of +/- 5 ° C. 15. The co-crystal according to claim 7, wherein the co-crystal former is 4-hydroxybenzoic acid. |
| priorityDate | 2007-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.